Half-year report · HY
9987.TEDINET S100X0ID
Period2025-04-01 → 2025-09-30
Filed2025-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.22T | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥2.40T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.20T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥17.0bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥17.1bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥18.0bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥38.8bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.0bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥23.2bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥29.0bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥16.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥34.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥16.2bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥20.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.11T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.22T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥769.0bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥706.4bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥405.6bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥407.4bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥429.9bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥119.4bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥102.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥135.3bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥118.6bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥142.3bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥198.7bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥25.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥65.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥56.6bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥7.4bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥20.4bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥3.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥15.9bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥35.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥228.09 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥454.58 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥261.16 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 34.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 36.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 35.2% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 48
| Segment | Item | Period | Value |
|---|---|---|---|
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥46.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥46.5bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥411m |
| The Healthcare Product Development Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥25.5bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥19.6bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.2bn |
| The Healthcare Related Services Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥20.9bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥12.4bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥8.5bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥521m |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.18T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.15T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥26.0bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥14.2bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥203.4bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥3.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥200.0bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥532m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.22T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥254.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥16.8bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥46.7bn |
| The Community Healthcare And Nursing Care Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥7m |
| The Community Healthcare And Nursing Care Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥126m |
| The Healthcare Product Development Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥26.2bn |
| The Healthcare Product Development Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.9bn |
| The Healthcare Product Development Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥20.2bn |
| The Healthcare Product Development Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.3bn |
| The Healthcare Related Services Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥21.4bn |
| The Healthcare Related Services Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥11.8bn |
| The Healthcare Related Services Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| The Healthcare Related Services Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥512m |
| The Pharmaceutical Distribution Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.16T |
| The Pharmaceutical Distribution Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.13T |
| The Pharmaceutical Distribution Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥25.6bn |
| The Pharmaceutical Distribution Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥14.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥137.5bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥134.1bn |
| The Specialty Drug Contract Distribution Business Reportable Segment Memberreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥377m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.39T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.20T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥189.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥16.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 497
| Item | Context | Value | Unit |
|---|---|---|---|
| Address major shareholders | InterimInstant_No4MajorShareholdersMember | Original text (Japanese)名古屋市昭和区 | |
| Name major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)別 所 昌 樹 | |
| Address major shareholders | InterimInstant_No5MajorShareholdersMember | Original text (Japanese)東京都渋谷区 | |
| Name major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Address major shareholders | InterimInstant_No6MajorShareholdersMember | Text · Plus | |
| Name major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)公益財団法人鈴木謙三記念医科学応用研究財団 | |
| Address major shareholders | InterimInstant_No7MajorShareholdersMember | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Name major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)鈴 木 慶 子 | |
| Address major shareholders | InterimInstant_No8MajorShareholdersMember | Original text (Japanese)名古屋市瑞穂区 | |
| Name major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)スズケングループ従業員持株会 | |
| Address major shareholders | InterimInstant_No9MajorShareholdersMember | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Name major shareholders | InterimInstant_No10MajorShareholdersMember | Original text (Japanese)ＪＰ ＭＯＲＧＡＮ ＣＨＡＳＥ ＢＡＮＫ ３８００５５（常任代理人 ㈱みずほ銀行決済営業部） | |
| Address major shareholders | InterimInstant_No10MajorShareholdersMember | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | Original text (Japanese)単元株式数は100株であります。 | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | Original text (Japanese)同上 | |
| Description issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | － | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)㈱スズケン | |
| Address of shareholder treasury shares etc | InterimInstant_Row1Member | Original text (Japanese)名古屋市東区東片端町８番地 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated financial statements financial information | InterimDuration | Text · Plus | |
| Note on independent audit financial information | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated balance sheet (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of comprehensive income (text) | InterimDuration | Text · Plus | |
| Type1 semi annual consolidated statement of cash flows (text) | InterimDuration | Text · Plus | |
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and semi annual financial statements (text) | Prior1InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1InterimDuration | Text · Plus | |
| Description of nature of differences between profit loss of reportable segments total and semi annual financial statements (text) | InterimDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | InterimDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |